Tibotec Therapeutics, makers of the protease inhibitor Prezista (darunavir), informed community members last week of its decision to discontinue manufacture of the 300 mg Prezista tablet. Prezista was approved for use in 2006, and a 600 mg Prezista tablet was released earlier this year. Prezista is currently approved for use in adults at 600 mg plus 100 mg Norvir (ritonavir) twice daily (there is no approved dose for pediatric use).
Company officials stated that the decision to discontinue the 300 mg tablet was based in part to avoid confusion between the two tablets, and that they been working aggressively with providers in an effort to educate their patients regarding the newer 600 mg tablet. The 300 mg tablet will be available until current supplies are depleted, and will also be available on a special needs basis. Anyone with medical questions regarding Prezista can call 1-877-REACHTT (732-2488).